Part A: Clinical Study Protocol SC12: Safety of a single dose of 5 mg of hLF1-11 given to autologous haematopoietic stem cell transplant recipients.

AM-Pharma B.VRumpsterweg 6 3981 AK Bunnik Tel +31 (0) 30 228 92 22 Fax +31 (0) 30 228 92 200 个研究点目标入组 8 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

•1. Admitted for an autologous HSCT after myeloablative therapy with high-dose melfalan;
•2. Managed with a 4-lumen central venous catheter;

•1. A history of, or presence of, significant respiratory, cardiovascular, neurological, haematological, endocrine, gastro intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs (as judged clinically relevant by the investigator);
•2. Participation in a study with a new chemical entity or new molecular entity 3 months before or participation in a study with a registered drug less than 5 times of the half life of the registered drug before entering the study;

发起方

AM-Pharma B.VRumpsterweg 6 3981 AK Bunnik Tel +31 (0) 30 228 92 22 Fax +31 (0) 30 228 92 20